Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety of AD-NP1, a Humanized Monoclonal Antibody Targeting Human ENPP1

NCT07762001 is registered in ClinicalTrials.gov with Arjun Deb, MD as lead sponsor.

NCT NCT07762001
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07762001 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety of AD-NP1, a Humanized Monoclonal Antibody Targeting Human ENPP1
Lead sponsor
Arjun Deb, MD
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 2, 2026
Completion date
May 1, 2028
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dose escalation, maximum tolerated dose